AlphAIAlphAI — Financial news for AI agents
investing.comOCT 163 min read$CTY

City Therapeutics prices upsized IPO at $18 per share

City Therapeutics (NASDAQ:CTY) priced its IPO at $18 per share, offering 11.11M shares for ~$200M. Underwriters have a 30-day option for additional shares. Trading begins on Nasdaq under CTY. The company focuses on RNA interference therapeutics.

Original reporting
investing.com
Published Oct 16, 2026, 2:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 2:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefIPO
Primary signal
$CTY
Bullish
medium confidence
Mentioned
$CTY
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CTYBullishMed
01

Why it matters

The priced and upsized IPO provides fresh capital and establishes a tradable equity for CTY, making the event relevant for positioning around first trading and early liquidity conditions.

02

Market read

Traders can act on the new listing details: IPO price, upsized share count, gross proceeds, and the expected start of trading today.

03

What to watch

Underwriter option size, lockup terms (not provided), and the company’s cash runway versus upcoming clinical milestones will likely matter more than the $18 reference price.

Relevance 8/10Novelty 8/10Timing: pre-market/first trading day after IPO pricing

Background

City Therapeutics is a clinical-stage biotechnology company developing RNA interference therapeutics, with programs including CITY-FXI, CITY-RBP4, and CITY-TFR2.

Company-level read

Ticker impact

$CTYBullishMedium confidence
Context

City Therapeutics priced an upsized IPO at $18, selling 11,111,111 shares plus a 30-day option for 1,666,666 more, starting Nasdaq trading today.

Expected impact

Likely initial volatility as the market reprices the new listing and digests the priced offering size and expected gross proceeds.

Evidence & confidence

The article discloses the IPO price, upsized share count, gross proceeds, and the expected start of trading under CTY, which are direct inputs to first-trade positioning and demand expectations.

Market effects

Sector

Adds a new clinical-stage RNAi biotech listing, which can marginally affect biotech IPO sentiment and near-term peer comps.

Regional

Primarily US Nasdaq microstructure impact via a new ticker and float.

Global

Limited beyond US biotech IPO flow sentiment.

Counterpoint

What could challenge this read

IPO pricing can be less informative than post-listing demand and allocation outcomes; early trading may fade if aftermarket demand is weak.

Key entities

  • company
    City Therapeutics, Inc.

    Clinical-stage RNA interference therapeutics developer that priced and upsized its IPO at $18 per share.

  • venue
    Nasdaq Global Market

    Exchange where CTY is expected to begin trading under ticker symbol CTY.

  • regulator
    U.S. Securities and Exchange Commission (SEC)

    Declared the registration statements effective on October 15, 2026.

Read at source← All news

StoryCity Therapeutics upsizes IPO, pricing 11.1 M shares at $18 each

Also covered by

4 outlets

Related articles

OCT 16
$CTYHighAI 8/10

City Therapeutics Prices Upsized $200 Mln IPO At $18/shr

City Therapeutics (CTY) priced its upsized IPO at $18 per share, raising $200M from 11M shares. Underwriters have a 30-day option for additional shares. Trading starts Oct 16, 2026, on Nasdaq. The company focuses on RNAi therapeutics for diseases like thromboembolic conditions and retinal diseases.

rttnews.com2 min
OCT 16
$CTYHighAI 9/10

City Therapeutics, Inc. Prices Upsized $200M IPO at $18

City Therapeutics priced an upsized IPO of 11.1M shares at $18 each, raising $200M. Shares will begin trading on Nasdaq as CTY on Oct. 16, 2026, subject to conditions. The company has no prior public trading history and plans to use proceeds for its clinical-stage RNAi pipeline.

tradingview.com1 min
OCT 9
$CTYHighAI 8/10

City Therapeutics IPO: RNAi biotech seeks up to $185 million

City Therapeutics, a biotech developing RNAi drugs, filed for an IPO seeking up to $184.7M, offering 9.7M shares at $17-$19 each. The company plans to list on Nasdaq under CTY. Its lead candidate, CITY-FXI, showed promising Phase 1 trial results. The company has raised $238.8M in equity and reported a $53.4M net loss for H1 2026. Proceeds will fund clinical development and research. (350 characters)

finance.yahoo.com2 min
OCT 16
$IAMHighAI 9/10

Iambic Therapeutics IPO Raises $150M, Stock Jumps

Iambic Therapeutics (IAM) raised $150M in its IPO, priced at $16, and saw shares jump 18% to close at $18.91. The company, which uses AI for drug discovery, has partnerships with AbbVie, Takeda, and Nvidia. It reported $12.8M revenue and a $50.1M net loss for H1 2026. Proceeds will fund oncology programs.

briefs.co2 min